Molteni Farmaceutici

What Molteni Farmaceutici does

Molteni Farmaceutici is a privately held, family-owned Italian specialty pharmaceutical company founded in 1892 in Florence, now headquartered in a 10,000 sqm consolidated facility in Scandicci with a 300+ headcount. It operates across four core therapeutic areas — addiction treatment (SERD-channel opioid dependence therapies including methadone and buprenorphine products, plus its Farma Leader subsidiary for opioid-dependence dispensing devices), pain management (morphine oral solution such as Oramorph, non-opioid lozenge BupiZenge via OncoZenge, and alcohol-use-disorder candidate AD04 via Adial), anaesthesia, and wound care (where its proprietary Photodynamic Therapy platform built around the RLP068/Cl photosensitizer is delivered through CE-marked VULNOFAST gels, VULNOLIGHT light source, and ELKOFAST device family). The company also recently entered oncology supportive care via the Evive Biotech Ryzneuta partnership and medical cannabis via Tilray Medical.

The business model combines in-house specialty manufacturing (sterile vials in glass and plastic, single-dose vials, oral liquids, and nasal sprays at 7.6 million packages / 20.7 million units annually) with a license-in / license-out commercialization engine: recent deals include exclusive European rights for AD04 (~$60M total potential value), exclusive Italian-Polish rights for Ryzneuta, exclusive European rights plus commercial-scale manufacturing for BupiZenge (15% royalties, EUR 3.3M milestones), and LATAM distribution of Oramorph via SteinCares across Ecuador, Brazil, and Mexico. Distribution reaches 35+ countries through direct field sales in Italy and Poland (Molteni Farmaceutici Polska since 1994), channel partners elsewhere, and qualified-supplier status with major NGOs for Opioid Substitution Treatment in developing countries.

The company is one of Italy's FAB13 leading pharma companies, holds ISO 9001, ISO 13485 (Medical Devices BU), and the Borsa Italiana Elite Certificate, and is led by CEO Gianluca Corbinelli. Ownership remains concentrated with the third entrepreneurial family that took control in 1972, with no disclosed venture, private-equity, or public-market backing.

Name

Molteni Farmaceutici

Legal name

L. MOLTENI & C. DEI F.LLI ALITTI Società di Esercizio S.P.A.

Website

https://moltenifarma.it

Company type

Private

Founded year

1892

Operating status

Operating

Headcount range

251–500 employees

Short description

Molteni Farmaceutici is a family-owned Italian specialty pharmaceutical company (founded 1892, 300+ staff) that manufactures addiction-treatment, pain-management, anaesthesia, and wound-care products, including a proprietary Photodynamic Therapy platform, and distributes them in 35+ countries through in-house sales, channel partners, and licensing deals.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (33911), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Specialty pharmaceuticals
• Addiction treatment medications
• Pain management therapies
• Medical devices manufacturing
• Pharmaceutical distribution

Headquarters

HQ city

Scandicci

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue from manufacturing and selling specialty pharmaceutical products including pain management therapies, addiction treatment medications, anaesthetics, and medical devices. The company produces sterile vials, oral liquids, and nasal sprays with annual production of 7.6 million packages (20.7 million units).
2. Licensing and Partnership Revenue: Revenue from exclusive commercialization agreements with partners such as royalties on BupiZenge sales (15%), milestone payments, and tiered royalties on European net sales of licensed products.
3. Distribution and Supply Agreements: Revenue from distributing pharmaceutical products through international partnerships, including exclusive marketing and distribution of products like Oramorph in Latin American markets.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

Molteni Farmaceutici manufactures and commercializes specialty pharmaceutical products and medical devices across four therapeutic areas: addiction treatment (opioid substitution therapies, alcohol use disorder), pain management (analgesics, cancer pain), anaesthesia, and wound care (photodynamic therapy medical devices). The company operates an integrated in-house manufacturing capability producing 7.6 million packages and 20.7 million units annually (sterile vials, single-dose vials, oral liquids, nasal sprays), and distributes its portfolio through institutional healthcare channels in over 35 countries.

Product overview

Molteni Farmaceutici is an Italian specialty pharmaceutical company founded in 1892, primarily specializing in pain therapy and substance dependence treatment. The company operates a diversified portfolio including: (1) a Photodynamic Therapy (PDT) Platform comprising medical devices (VULNOFAST® gel, VULNOLIGHT®, VULNOFAST® plus, ELKOFAST® gel 0.3%) for wound care; (2) pharmaceutical products including BupiZenge™ (non-opioid oral pain treatment), AD04 (alcohol use disorder treatment), Ryzneuta® (G-CSF for neutropenia), and Oramorph® (morphine oral solution); and (3) the Farma Leader service for opioid dependence treatment devices. The company also maintains ISO 13485-certified in-house manufacturing capabilities producing sterile vials, oral liquids, and nasal sprays. With over 300 employees and operations in 40+ countries, Molteni serves therapeutic areas including addiction treatment, pain management, anaesthesia, and wound care.

Differentiator

Problem solved

Functional benefit

Products and services

• VULNOFAST gel Photodynamic therapy gel medical device for the treatment of skin lesions and ulcers, including infected diabetic foot ulcers. CE Marked in 2013.
• VULNOLIGHT Proprietary light source device for photodynamic therapy activation. VULNOLIGHT 4.0 CE Marked in 2022 under MDR Regulation.
• VULNOFAST plus Dense liquid formulation medical device for photodynamic therapy, upgraded with CE Mark under MDR Regulation in 2023.
• ELKOFAST gel 0.3% Non-sterile formulation medical device for photodynamic therapy applications. CE Mark upgraded under MDR in 2023.
• AD04 Genetically targeted serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder treatment in heavy drinking patients. Commercialized in Europe through partnership with Adial Pharmaceuticals.
• BupiZenge Novel non-opioid oral lozenge formulation of bupivacaine for treating oral pain, initially focused on pain associated with oral mucositis. Commercialized in Europe through partnership with OncoZenge.
• Ryzneuta (efbemalenograstim alfa) Next-generation long-acting G-CSF (granulocyte colony-stimulating factor) for chemotherapy-induced neutropenia. Commercialized in Italy and Poland through partnership with Evive Biotech.
• Oramorph Novel morphine oral solution for severe pain management. Distributed in Latin America through partnership with SteinCares.
• Farma Leader Italian service company of the Molteni Group dedicated to design, development, distribution, and maintenance of medical devices and software for dispensing medications to patients with opioid dependence.

Quantifiable outcome

• 7.6 million packages and 20.7 million units produced annually
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Evive BiotechcoreChannel Partner/ Reseller/ Distributor · 16 April 2026Strategic agreement granting Molteni exclusive rights to commercialize Ryzneuta (efbemalenograstim alfa), a next-generation long-acting G-CSF for chemotherapy-induced neutropenia, in Italy and Poland. Molteni leads regulatory, market access, and commercialization activities.
• Adial PharmaceuticalscoreStrategic or Co-development Partner · 3 March 2026Collaboration framework agreement for exclusive European commercialization of AD04, a serotonin-3 receptor antagonist for Alcohol Use Disorder treatment. Deal includes upfront payment, milestone payments, and tiered royalties (high single digits to low double digits) with total potential value of nearly $60 million. Molteni granted exclusivity period for due diligence and commercial launch assessment.
• Tilray Medical (Tilray Brands)coreChannel Partner/ Reseller/ Distributor · 22 January 2026Partnership for distribution of EU-GMP certified medical cannabis products (flowers and oils) through hospital and pharmacy channels in Italy. Tilray Medical Italia operates under Italian Ministry of Health regulations with physician-focused initiatives.
• OncoZenge ABcoreStrategic or Co-development Partner · 1 December 2025Expanded partnership where Molteni assumes commercial-scale manufacturing responsibility for BupiZenge (non-opioid oral pain treatment) for European market. Original agreement includes royalties of 15% and milestone payments totaling up to EUR 3.3 million at cumulative net sales of EUR 40 million.
• SteinCaresminorChannel Partner/ Reseller/ Distributor · 1 January 2025Commercialization agreement for exclusive marketing and distribution of Oramorph (novel morphine oral solution) in Ecuador, Brazil, and Mexico. Partnership expands access to pain treatment in Latin America.
• CamurusminorChannel Partner/ Reseller/ Distributor · 1 March 2023Partnership for commercialization of buprenorphine-based medication for opioid dependence treatment in Italy.
• International NGOs (Opioid Substitution Treatment)minorChannel Partner/ Reseller/ DistributorRecognized as qualified supplier by major NGOs implementing and maintaining Opioid Substitution Treatment (OST) programs in developing countries.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/molteni-farmaceutici

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molteni Farmaceutici